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Background: Tenofovir and rifampicin have been individually implicated in renal toxicity characterized by 
electrolytes imbalance; hence concurrent use in human immunodeficiency virus/tuberculosis co-infection might 
induced synergistic electrolytes imbalance and kidney damage. 
Objectives: This study comparatively evaluated the effects of treatment with tenofovir, rifampicin and a combination 
of tenofovir-rifampicin on serum electrolytes levels and kidney histology of male albino rats.   
Methodology: Healthy adult male albino rats used for this study were divided into five (5) groups of sixteen animals 
(16) each. Animals in group A (placebo control) were treated orally with water while animals in group B (solvent 
control) were treated orally with arachis oil. Animals in groups C-E were treated orally with 80mg/kg of rifampicin, 
32 mg/kg of tenofovir and tenofovir-rifampicin combination for 1-8 weeks respectively. At the end of drug therapy 
the animals were sacrificed and blood samples collected. Serum was extracted from the blood samples and analyzed 
for chloride, sodium, calcium, potassium and bicarbonate levels. Animals were dissected, kidney collected and 
analyzed for histopathological changes.  
Results: Treatment with a combination of tenofovir-rifampicin for 1-8 weeks did not produce significant (p>0.05) 
time-dependent effects on serum electrolytes when compared to treatment using individual doses of these agents. 
Kidneys of animals treated with these agents showed tubular necrosis, collapsed glomerular and collection of fibrous 
material on bowman’s space. 
Discussion and Conclusion: Treatment with a combination of tenofovir-rifampicin did not produce synergistic 
effects on serum electrolytes and kidney damage. The use of tenofovir – rifampicin combination in human 
immunodeficiency virus/tuberculosis co-infection may not be associated with electrolytes imbalance and kidney 
damage considering the dose level used for this study.   
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1. Introduction 
The kidney performs several excretory and regulatory 
functions including blood pressure control and 
maintenance of extracellular environment. It is 
responsible for the composition and volume of 
circulating fluids with respect to water and electrolytes 
balance and acid-base status (Ferguson and Walker, 
2012). Kidney damage by drugs and infections could 
lead to multiple disturbances of electrolytes metabolism 
and endocrine regulations (Peter, 1991). Serum 
electrolytes imbalance and altered mineral metabolism 
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which occurred due to drug treatment have been found 
to contribute to bone diseases, cardiovascular diseases 
and other clinical problems (Ugwuja and Eze, 2007). 
The high extent of delivery of materials including 
xenobiotics, via their passage through the tubular 
lumen may contribute to electrolyte imbalance and 
kidney damage (Hagos and Wolff, 2010).  
The concurrent use of medications due to comorbidities 
could induce electrolytes abnormalities through 
interference with the absorption of electrolytes; alter 
hormonal responses affecting homeostasis, as well as 
direct impact on organ function responsible for 
maintaining electrolytes balance (Cruz et al, 2003; 
Buckley et al, 2010). One of the co-morbid conditions 
that necessitate concurrent use of medications is human 
immunodeficiency virus/tuberculosis (HIV/TB) 
infection. There are well established epidemiological 
and biological synergies between HIV and TB, 
influencing the distribution, progression and outcomes 
of both infections. The HIV epidemic is a key factor 
behind the resurgence in TB incidence worldwide 
(UNAIDS, 2013). The established relationship between 
HIV and TB infections has necessitates co-therapy with 
antiretroviral drugs and anti-tuberculosis drugs. These 
include cases of co-therapy with tenofovir containing 
regimes and rifampicin containing regimens (WHO, 
2007).  
Co-therapy with rifampicin and tenofovir containing 
regimes might be of therapeutic concern due to the 
individual nephrotoxic effects of rifampicin and 
tenofovir. Rifampicin is usually considered safe, but 
cases of rifampicin renal toxicity have been reported 
sporadically. Since the first description in 1971, there 
are more reported cases of renal toxicity characterized 
by acute tubulointerstitial nephritis and/or acute 
tubular necrosis, interstitial lesions, isolated or super 
imposed glomerular injury and electrolytes imbalance 
(Fenfield et al, 1999; Young and Killingworth, 2002; 
Yoshioka et al, 2002; Neugarten, 1983).  Most cases of 
rifampicin-related renal failure are secondary to drug-
induced haemolytic anaemia. Acute interstitial 
nephritis, rapidly progressive glomerulonephritis are 
usually characterized by proteinuria with acute onset 
deterioration of renal functions and light-chain 
proteinuria (Power et al, 1983; Prakash et al, 2001).  
The use of TDF has been associated renal toxicity 
characterized by kidney histopathological changes. 
Large clinical studies and post-marketing data support a 
benign renal profile for tenofovir; numerous cases of 
kidney injury in humans raise concern for nephrotoxic 
potential. Animal studies show that tenofovir causes 
mitochondrial DNA depletion and mitochondrial 
toxicity (Herliz, 2010; Adikwu et al, 2014). Renal 
proximal tubules from HIV + transgenic mice exposed to 
tenofovir showed ultrastructural mitochondrial 
abnormalities (irregular shapes with sparse, 
fragmented cristae) and decreased mtDNA levels, which 
paralleled the ultrastructural mitochondrial 
abnormalities (Kholer et al, 2009). Also some reported 
cases of tenofovir-induced renal toxicity were 
characterized by serum electrolytes imbalance 
(Zimmerman et al, 2006; Tourret et al, 2013; Patel et al, 
2010; Kapitsinou and Ansari, 2008; Mathew and Kanus, 
2006). Co-therapy with tenofovir and rifampicin may 
present important safety concerns on serum 
electrolytes levels and kidney histology. This study was 
designed to comparatively evaluate the effects of 
treatment with rifampicin, tenofovir and a combination 
of tenofovir- rifampicin on serum electrolytes and 
kidney histology of albino rats. 
2. Materials and Methods 
2.1 Animals 
Eighty (80) adult male albino rats of average weight 
330 ±5 g were used for this study.  The animals were 
obtained from the animal house of the Department of 
Pharmacology and Toxicology, Madonna University, 
Elele, Rivers State. The animals were allowed to 
acclimatize for 14 days and had free access to food and 
water ad libitum. 
2.2 Drugs 
Rifampicin used for this study was manufactured by 
Mancare Pharmaceuticals, India while pure sample of 
tenofovir disoproxil fumarate was purchased from 
Shijiazhuang Aopharm Import & Export Trading Co., 
Ltd. Shijiazhuang, China. Other chemicals used in this 
study were of analytical grade. The doses of rifampicin 
and tenofovir disoproxil fumarate used for this study 
were 80mg/kg and32 mg/kg respectively (CDC, 2003; 
Viread, 2013).  Rifampicin and tenofovir powder were 
suspended in arachis oil. 
2.3 Grouping of Animals and Drug Administration 
Animals were group into five groups A- E of 16 animals 
per group. Animals in each group were further sub 
divided into four groups of four animals each. Animals 
in group A (placebo control) were orally treated with 
water, while animals in group B (solvent control) were 
orally treated with Arachis oil. Animals in groups C-E 
were orally treated with 80 mg/kg of RIF, 32 mg/kg of 
TDF and a combination of TDF- RIF orally for 1-8 weeks 
respectively. 
2.4 Collection of Sample for Analysis  
At 1, 2, 4 and 8 weeks , after overnight fast, 2mls of 
blood samples were collected from the rats under  
chloroform anesthesia, by cardiac puncture into sterile 
sample container  and allowed to clot. Thereafter, 
serum was separated by centrifugation at 1200 rpm for 
15 min and used for analysis. The animals were then 
killed by over dose of chloroform anesthesia; kidneys 
were dissected out, cleaned off the extraneous tissue, 
weighed and evaluated for histopathological changes. 
2.5 Evaluation of Serum Electrolytes  
Potassium and sodium were determined using flame 
photometric methods, while chloride and bicarbonate 
levels were determined using titrimetric methods.  
2.6 Histopathological Analysis 
The collected kidney tissues were fixed with 10% 
buffered formalin, dehydrated in ascending grades of 
ethanol, and cleared in xylene. The tissues were later 
embedded in paraffin wax and sections of 5 cm in 
thickness were prepared and stained with hematoxylin 
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and eosin. The stained sections were then examined 
under light microscopy and photomicrographs of the 
relevant stained sections were taken with the aid of a 
light microscope. 
2.7 Statistical Analysis 
This was done using Graph Pad Prism 5 statistical 
package and ANOVA for comparison of the means of the 
various groups. The means and standard errors were 
calculated and test groups results compared with that of 
the control groups. A p-value < 0.05 was considered 
significant. 
2.8 Ethical considerations 
All animals used for this study were handled in 
accordance with the international, national and 
institutional guidelines for care and use of laboratory 
animals in biomedical research as promulgated by the 
Canadian Council of Animal Care (2009). 
3.  Results 
Treatment with TDF for 1-8 weeks did not produce 
significant (p>0.05) time-dependent effects on serum 
electrolytes when compared to the control values. Also, 
serum electrolytes remained virtually normal without 
any significant (p>0.05) difference when compared to 
the control values following treatment with RIF for 1-
8weeks.  
Furthermore, observations in this study show that 
treatment for 1-8 weeks with a combination of TDF-RIF 
did not produce significant (p>0.05) time-dependent 
effects on serum electrolytes when compared to the 
control values and when compared to treatment using 
individual doses of TDF and RIF (Table 1).  
Table 1: Effects of treatment with tenofovir, rifampicin and tenofovir-rifampicin combination on serum electrolytes of 
male albino rats 
Dose WK1 WK2 WK4 WK8 
 Serum Sodium (mmol/L) 
Control                                126.5±2.15 126.7±1.21 125.9±1.32 127.1±1.43 
TDF 80mg/kg 127.1±1.20 126.1±2.11 126.3±1.15 128.5±1.40 
RIF 32mg/kg 126.6±0.70 125.7±1.21 127.3±1.10 126.7±1.24 
TDF/RIF 127.2±0.12 126.2±1.14 127.6±0.12 128.6±1.33 
 Serum Potassium (mmol/L) 
Control 3.49±0.07 3.47±0.03 3.50±0.04 3.48±0.01 
TDF 80mg/kg 3.48±0.01 3.46 ±0.05 3.51±0.02 3.47±0.05 
RIF 32mg/kg 3.51±0.06 3.48±0.01 3.50±0.04 3.49±0.03 
TDF/RIF 3.50±0.07 3.53±0.03 3.52 0.02 3.48±0.04 
 Serum Chloride (mmol/L) 
Control 120.5±3.21 120.7±3.23 122.5±0.14 121.6±4.10 
TDF 80mg/kg 121.3±2.21 123.2±1.20 119.7±3.14 124.1±0.25 
RIF 32mg/kg 120.7±2.64 124.6±0.76 123.8±2.11 126.5±3.14 
TDF/RIF 122.4±1.52 125.1±2.14 122.3±1.14 128.2±3.20 
 Serum Bicarbonate (mmol/L) 
Control 22.5±1.10 22.4±1.10 24.6±0.15 21.9±1.22 
TDF 80mg/kg 22.4±0.22 22.0 ±0.13 22.1±0.01 19.9±0.03 
RIF 32mg/kg 22.3±0.50 19.8±0.21 22.2±0.05 20.3±0.02 
TDF/RIF 21.7±0.70 20.4±0.21 20.6± 0.32 21.0±1.00 
 Serum Calcium (mg/dL) 
Control 11.49±0.07 11.47±0.03 11.50±0.04 11.46±0.01 
TDF 80mg/kg 11.50±0.21 11.48 ±0.05 11.51±0.02 11.60±0.15 
RIF 32mg/kg 11.51±0.16 11.52±0.31 11.50±0.24 11.40±0.03 
TDF/RIF 11.60±0.07 11.53±0.23 11.52 ±0.02 11.48±0.04 
  TDF: tenofovir, RIF: rifampicin.  
  Results are expressed as mean ± SEM, n= 4. 
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Figure 1: Photomicrograph of H and E stained section of 
the kidney of control rat treated with water for 4 weeks 
showing normal kidney histology. (x200) 
Figure 2; Photomicrograph of H and E stained section of 
the kidney of rat treated with 80mg/kg of rifampicin for 4 
weeks showing sloughing of the epithelial cells of the 
tubules and collection of fibrous material on the 
Bowman’s space (x200) 
 
  
Figure 3; Photomicrograph of H and E stained section of 
the kidney of rat treated with 32mg/kg of tenofovir for 4 
weeks showing tubular necrosis and collection of fibrous 
material on the Bowman’s space (x200)  
Figure 4: Photomicrograph of H and E stained section of 
the kidney of rat treated with 32mg/kg of tenofovir and 
80 mg/kg rifampicin for 4 weeks showing tubular 
necrosis, collapsed glomerular and fibrous material on 
Bowman’s space (x200) 
 
Kidney of animals treated with tenofovir, rifampicin and 
a combination of TDF-RIF show various degrees of 
histopathological changes which include tubular 
necrosis, collapsed glomerular and collection of fibrous 
material on Bowman’s space (Figure1-4). 
4. Discussion 
This study comparatively evaluated the toxicological 
effects of tenofovir, rifampicin and a combination of 
tenofovir-rifampicin on serum electrolyte and kidney 
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histology of albino rats. Effects on serum electrolytes 
evaluated include sodium (Na+), potassium (K+), 
calcium (Ca2+) chloride (Cl-) and bicarbonate(HCO3) 
(Hall and Guyton, 2006; Buckley et al, 2010). 
Electrolytes play important role in intermediary 
metabolism and cellular function, including enzyme 
activities and electrical gradients (Bootman and Peter, 
2001; Lobo, 2004; Meletis, 1990; Tripathi et al, 2011).   
In this study, there was no electrolytes imbalance 
observed in animals treated with individual doses of 
tenofovir and rifampicin. Also treatment with a 
combination of tenofovir-rifampicin did not produce 
any additive or synergistic toxicological effect on serum 
electrolytes. Despite absence of electrolytes imbalance 
in animals treated with these agents, tubular necrosis, 
collapsed glomerular and collection of fibrous material 
on bowman’s space were observed in the kidneys of 
animals treated with these agents. This may be due to 
the ability of the kidney to concentrate these agents as 
reported by some scholars (Lebretch et al, 2009; Cote et 
al, 2000). Observation in this study shows that co-
therapy with tenofovir-rifampicin in human 
immunodeficiency virus/ tuberculosis co-infection may 
not be associated with fluctuations in serum 
electrolytes and kidney damage with respect to doses 
used for this study.  
In this present study, lack of serum electrolytes 
imbalance observed in animals treated with tenofovir is 
at variance with the work of Ramamoorthy et al, 2012 
who treated rats with 600mg/kg of tenofovir for 35 
days and reported abnormalities in electrolytes. 
Observed variation may be due to higher doses of 
tenofovir used by these authors. Tenofovir has been 
reported to be associated with metabolic acidosis that 
occurs due to defective bicarbonate reabsorption in the 
proximal tubule which is at variance with our 
observation (Baum, 1993; Mukhyaprana et al, 2014).  
Histopathological damage observed in the kidneys of 
tenofovir treated animals is in agreement with previous 
reports (Adaramoye et al, 2012; Liborio 2008; 
Rammoorthy et al, 2014; Shaaf et al, 2003). Histological 
alterations observed in the kidneys of animals treated 
with tenofovir may be due to accumulation in proximal 
renal tubular cells which can stimulate proximal tubule 
mitochondria damage leading to the production of 
oxidative radicals and the depletion of kidney 
antioxidants. Mitochondria are responsible for energy 
production and contain oxidative radicals which are 
released during mitochondria damage (Lebretch et al, 
2009; Lewis et al, 2003; Cote et al, 2000; Tanji et al, 
2009) 
In this study, lack of electrolytes imbalance observed in 
animals treated with rifampicin contradicts the work of 
Peter and Chike, who treated rats with 1.10mg/120gBW 
and 0.55mg/120g BW of rifampicin for 20-60 days and 
reported electrolytes imbalance (Peter and Chike, 
2013). Observation in this study is also at variance with 
reported cases of rifampicin-induced serum electrolytes 
imbalance by Min et al, 2013 and Rosati et al, 2013. 
Observed histopathological damage in the kidneys of 
rifampicin-treated animals is consistent with the work 
of Opromolla who reviewed cases of rifampicin 
associated renal failure and reported tubular necrosis 
as a common feature (Opromolla, 1992). Also, finding in 
this study is in agreement with the work of Min and 
colleagues who reported a case of rifampin induced 
tubulointersititial nephritis (Min et al, 2013) and Rosati 
et al  who reported rifampicin-associated interstitial 
tubulopathy (Rosati et al, 2013). Also, some scholars 
have reported tubular necrosis as a common and 
pronounce feature of rifampicin nephrotoxicity 
(Deviese et al, 1983; Flyn et al, 1974; Feinfeld, 1999; 
Geo et al, 2010). Histological alterations observed in the 
kidneys of animals treated with rifampicin may be due 
to immune complex deposition with compliment 
fixation leading to glomerular endothelial swelling, 
obstruction of blood flow and tubular ischemia (Chan et 
al, 1975). This is supported by the work of Muthukumar 
and others who reported immune complex deposition 
in blood vessels or interstitium which caused 
glomerular endotheliosis leading to tubular injury 
(Muthukumar et al, 2002). Rifampicin nephrotoxicity 
may be associated with destruction and depletion of 
tubular mitochondria DNA which may result in the 
release of oxidative radicals and depletion of 
antioxidants. 
5. Conclusion 
Observations in this study show that treatment with 
tenofovir-rifampicin combination was not associated 
with synergistic toxicological effect on serum 
electrolytes. Tubular necrosis, collapsed glomerular and 
collection of fibrous material on bowman’s space were 
observed in the kidneys of treated animals. These 
observations show that co-therapy with these agents in 
human immunodeficiency virus/tuberculosis co-
infection may not be associated with electrolytes 
imbalance and kidney damage. 
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